



**October 26, 2017**

**UPS OVERNIGHT MAIL**

Mr. Robert Fishman, President  
Lato Drug Co., Inc. dba Post Haste Pharmacy  
4401 Sheridan Street  
Hollywood, FL 33021

Dear Mr. Fishman:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Lato Drug Co., Inc. dba Post Haste Pharmacy, located at 4401 Sheridan Street, Hollywood, FL, 33021, from April 7, 2017, to April 13, 2017, by the U.S. Food and Drug Administration (FDA).

When the Agency concludes that an inspection is "closed" under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact me at 214-253-5288 or via e-mail at [john.diehl@fda.hhs.gov](mailto:john.diehl@fda.hhs.gov).

Sincerely,

John W.  
Diehl -S

Digitally signed by John W. Diehl -S  
DN: c=US, o=U.S. Government, ou=HHS  
ou=FDA, ou=People, cn=John W. Diehl -S  
0.3.243.19200300.100.1.1.2000099727  
Date: 2017.10.26 13:22:06 -0500

John W. Diehl  
Acting Director, Compliance Branch  
Office of Pharmaceutical Quality  
Operations, Division II

**Enclosure:** Establishment Inspection Report (EIR)

U.S. Food & Drug Administration  
Office of Pharmaceutical Quality Operations, Division II  
4040 North Central Expressway, Suite 300  
Dallas, Texas 75204-3158  
[www.fda.gov](http://www.fda.gov)